Dapagliflozin reduces the amplitude of shortening and Ca2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats
- 565 Downloads
In the management of type 2 diabetes mellitus, Dapagliflozin (DAPA) is a newly introduced selective sodium-glucose co-transporter 2 inhibitor which promotes renal glucose excretion. Little is known about the effects of DAPA on the electromechanical function of the heart. This study investigated the effects of DAPA on ventricular myocyte shortening and intracellular Ca2+ transport in streptozotocin (STZ)-induced diabetic rats. Shortening, Ca2+ transients, myofilament sensitivity to Ca2+ and sarcoplasmic reticulum Ca2+, and intracellular Ca2+ current were measured in isolated rats ventricular myocytes by video edge detection, fluorescence photometry, and whole-cell patch-clamp techniques. Diabetes was characterized in STZ-treated rats by a fourfold increase in blood glucose (440 ± 25 mg/dl, n = 21) compared to Controls (98 ± 2 mg/dl, n = 19). DAPA reduced the amplitude of shortening in Control (76.68 ± 2.28 %, n = 37) and STZ (76.58 ± 1.89 %, n = 42) ventricular myocytes, and reduced the amplitude of the Ca2+ transients in Control and STZ ventricular myocytes with greater effects in STZ (71.45 ± 5.35 %, n = 16) myocytes compared to Controls (92.01 ± 2.72 %, n = 17). Myofilament sensitivity to Ca2+ and sarcoplasmic reticulum Ca2+ were not significantly altered by DAPA in either STZ or Control myocytes. L-type Ca2+ current was reduced in STZ myocytes compared to Controls and was further reduced by DAPA. In conclusion, alterations in the mechanism(s) of Ca2+ transport may partly underlie the negative inotropic effects of DAPA in ventricular myocytes from STZ-treated and Control rats.
KeywordsDiabetes mellitus SGLT2 inhibitors Dapagliflozin Ventricular myocytes Streptozotocin-induced diabetic rats
The work has been supported by a grant from the College of Medicine & Health Sciences, United Arab Emirates University. Research in our laboratory is also supported by LABCO, a partner of Sigma-Aldrich.
Conflicts of interest
The authors declare no conflicts of interest. The pharmaceutical industry has no influence or input in this scientific work.
- 1.International Diabetes Federation (2013) ATLAS. 6th ed. Brussels, BelgiumGoogle Scholar
- 3.Brownie S, Hunter L, Rossiter R, Hills AP, Robb W, Hag-Ali M (2014) Diabetes in the United Arab Emirates: the need for valid datasets for health service planning. Lancet Diabetes Endocrinol 14:70025–70027Google Scholar
- 4.Vaccaro O, Eberly LE, Neaton JD, Yang L, Riccardi G, Stamler J (2004) Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the multiple risk factor intervention trial. Arch Intern Med 164(13):1438–1443CrossRefPubMedGoogle Scholar
- 16.Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15(4):372–382PubMedCentralCrossRefPubMedGoogle Scholar
- 17.FDA Approves Invokana to treat type 2 diabetes. (2013) Food and Drug AdministrationGoogle Scholar
- 18.Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN (2008) Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51(5):1145–1149CrossRefPubMedGoogle Scholar
- 26.Howarth FC, Qureshi MA, Sobhy ZH, Parekh K, Yammahi SR, Adrian TE, Adeghate E (2011) Structural lesions and changing pattern of expression of genes encoding cardiac muscle proteins are associated with ventricular myocyte dysfunction in type 2 diabetic Goto-Kakizaki rats fed a high-fat diet. Exp Physiol 96(8):765–777CrossRefPubMedGoogle Scholar
- 28.Spurgeon HA, DuBell WH, Stern MD, Sollott SJ, Ziman BD, Silverman HS, Capogrossi MC, Talo A, Lakatta EG (1992) Cytosolic calcium and myofilaments in single rat cardiac myocytes achieve a dynamic equilibrium during twitch relaxation. J Physiol 447:83–102:83–102Google Scholar
- 29.Bassani JW, Yuan WL, Bers DM (1995) Fractional SR Ca release is regulated by trigger Ca and SR Ca content in cardiac myocytes. Am J Physiol 37:C1313–C1319Google Scholar
- 32.Salem KA, Qureshi MA, Sydorenko V, Parekh K, Jayaprakash P, Iqbal T, Singh J, Oz M, Adrian TE, Howarth FC (2013) Effects of exercise training on excitation-contraction coupling and related mRNA expression in hearts of Goto-Kakizaki type 2 diabetic rats. Mol Cell Biochem 380(1–2):83–96CrossRefPubMedGoogle Scholar